Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | HPGD | P15428 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | NMT1 | P30419 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 3/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | CLK1 | P49759 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2013271 | 0.86 | LMNA (0.47) | MAPTALDH1A1SMN1; SMN2KDM4EHPGD | |
| SCHEMBL31603107 | 0.72 | MAPT (0.63) | MAPTALDH1A1SMN1; SMN2KDM4EHPGD | |
| SCHEMBL620359 | 0.72 | MAPT (0.63) | MAPTALDH1A1SMN1; SMN2KDM4EHPGD | |
| SCHEMBL438203 | 0.71 | MAPT (0.62) | MAPTALDH1A1SMN1; SMN2KDM4EHPGD | |
| SCHEMBL2947439 | 0.71 | MAPT (0.62) | MAPTALDH1A1SMN1; SMN2KDM4EHPGD | |
| SCHEMBL544894 | 0.71 | MAPT (0.62) | MAPTALDH1A1SMN1; SMN2KDM4EHPGD | |
| Butane SCHEMBL3825261 | 0.70 | MAPT (0.61) | MAPTALDH1A1SMN1; SMN2KDM4EHPGD | |
| SCHEMBL2011734 | 0.69 | MAPT (0.45) | MAPTALDH1A1SMN1; SMN2KDM4EHPGD | |
| SCHEMBL2544566 | 0.69 | LMNA (0.68) | MAPTALDH1A1SMN1; SMN2KDM4EHPGD | |
| SCHEMBL30855071 | 0.68 | MAPT (0.61) | MAPTALDH1A1SMN1; SMN2KDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2721034-B1 | N-HETEROTRICYCLIC ANTIBIOTICS | BASILEA PHARMACEUTICA AG (CH) | 2016-07-20 | — | — | EP | disclosed |
| US-9321788-B2 | Tricyclic antibiotics | BASILEA PHARMACEUTICA AG (CH) | 2016-04-26 | — | — | US | disclosed |
| US-9120822-B2 | Tricyclic antibiotics | BASILEA PHARMACEUTICA AG (CH) | 2015-09-01 | — | — | US | disclosed |
| US-20150072975-A1 | TRICYCLIC ANTIBIOTICS | BASILEA PHARMACEUTICA AG | 2015-03-12 | — | — | US | disclosed |
| US-8927541-B2 | Tricyclic antibiotics | BASILEA PHARMACEUTICA AG (CH) | 2015-01-06 | — | — | US | disclosed |
| US-20140235855-A1 | Tricyclic Antibiotics | BASILEA PHARMACEUTICA AG (CH) | 2014-08-21 | — | — | US | disclosed |
| EP-2721034-A1 | TRICYCLIC ANTIBIOTICS | Basilea Pharmaceutica AG (CH) | 2014-04-23 | — | — | EP | disclosed |
| EP-2513115-B1 | TRICYCLIC ANTIBIOTICS | BASILEA PHARMACEUTICA AG (CH) | 2013-10-09 | — | — | EP | disclosed |
| WO-2012171860-A1 | TRICYCLIC ANTIBIOTICS | BASILEA PHARMACEUTICA AG (CH) | 2012-12-20 | — | — | WO | disclosed |
| EP-2513115-A1 | TRICYCLIC ANTIBIOTICS | Basilea Pharmaceutica AG (CH) | 2012-10-24 | — | — | EP | disclosed |
| US-20120245345-A1 | TRICYCLIC ANTIBIOTICS | BASILEA PHARMACEUTICA AG (CH) | 2012-09-27 | — | — | US | disclosed |
| WO-2011073378-A1 | TRICYCLIC ANTIBIOTICS | BASILEA PHARMACEUTICA AG (CH) | 2011-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120245345-A1 | TRICYCLIC ANTIBIOTICS | CBR1, CBR3, C1S | MAPT 4863/4885ALDH1A1 2967/4885SMN1; SMN2 2492/4885 |
| US-20140235855-A1 | Tricyclic Antibiotics | CBR1, CYP2S1, C1S | MAPT 4799/4885ALDH1A1 834/4885SMN1; SMN2 2840/4885 |
| US-20150072975-A1 | TRICYCLIC ANTIBIOTICS | TREH, MRPL21, SPOUT1 | MAPT 3446/4885ALDH1A1 2268/4885SMN1; SMN2 4423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.